PlainPharmaWatch

CMS Open Payments · Program Year 2024

Harrow Eye, LLC

Harrow Eye, LLC reported $1,094,856.71 across General Payments, Research, and Ownership to 11,566 physicians and teaching hospitals across 11,566 transactions.

$1.1M Above-median payer
All-tracks total
11,566 Top 10% volume
Transactions
11,566 Top 10% reach
Recipients
+$974.1K
General Payments vs PY2023

Harrow Eye, LLC reported $1,094,856.71 across all CMS Open Payments tracks (General + Research + Ownership) to 11,566 physicians and teaching hospitals in Program Year 2024 - ranking #602 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,094,856.71, averaging $94.66 per recipient.

Harrow Eye, LLC's payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

C

72/100

Total payments

F

20/100

Transaction volume

A

94/100

Physician reach

A

98/100

Payment type diversity

C

77/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer harrow-eye-llc Harrow Eye, LLC

$1.1M · #602/1,925 · 0.0% industry · PY2024

  • TOT $1.1M
  • RANK #602
  • SHARE 0.0%
  • TXN 11,566
  • RCP 11,566
  • CAT 6
  • GEN $1.1M
  • ΔGEN +$974.1K
  • TOP1 18.0%
  • PY 2024

Nearest volume peer: CONMED Corporation ($1.1M)

Neuronetics, Inc.$1.1MKyowa Kirin Co., Ltd$1.1MCONMED Corporation$1.1MHarrow Eye, LLC (this)$1.1MX4 Pharmaceuticals, Inc.$1.1M
All-tracks payment totals near Harrow Eye, LLC (CMS Open Payments PY2024)

Harrow Eye, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Harrow Eye, LLC's CMS-reported General Payments increased by $974.1K (+806.8%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2023: HARROW EYE, LLCPY2024: Harrow Eye, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$120.7KPY2024$1.1M
PY2023
$120,738.23
PY2024
$1,094,856.71

What the Data Shows for Harrow Eye, LLC

Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Harrow Eye, LLC that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.

"Food and Beverage" leads the 6-category general-payment breakdown below at $385.5K (35.2% of General Payments, 11,373 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Across 6 types of general payments, Harrow Eye, LLC's largest category was "Food and Beverage" at $385.5K - 35.2% of General Payments.

Harrow Eye, LLC reports 6 general-payment categories - the top three are Food and Beverage (35.2%), Honoraria (20.0%), and Compensation for Services Other Than Consulting (17.3%). The remaining 3 categories make up 27.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Harrow Eye, LLC divides its payments

Top payment categories by total reported dollar volume

1. Food and Beverage$385.5K2. Honoraria$219.5K3. Compensation for Services…$189.7K4. Grant$150.0K5. Consulting Fee$110.6K6. Travel and Lodging$39.5K
Payment Type Amount Transactions
Food and Beverage $385.5K 11,373
Honoraria $219.5K 58
Compensation for Services Other Than Consulting $189.7K 46
Grant $150.0K 4
Consulting Fee $110.6K 29
Travel and Lodging $39.5K 56

Recipient Concentration in General Payments

The five largest recipient relationships account for $511,057.62 (46.7%) of $1,094,856.71 in this company's General Payments records across 5,705 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Harrow Eye, LLC

The five named recipients with the highest reported General Payments from this company

Richard Adler$196.8KUday Devgan$150.0KMartin Makary$90.4KPaul Karpecki$42.4KRanjan Malhotra$31.5K
  1. 1

    Richard Adler

    $196,760.60 across 103 reported transactions

  2. 2

    Uday Devgan

    $150,000.00 across 4 reported transactions

  3. 3

    Martin Makary

    $90,357.05 across 8 reported transactions

  4. 4

    Paul Karpecki

    $42,416.60 across 18 reported transactions

  5. 5

    Ranjan Malhotra

    $31,523.37 across 33 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Harrow Eye, LLC ranks #602 of 1,925 by total payments (top 31% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,225 of 1,838 by HHI (bottom 33% least concentrated), a wider distribution than most similarly sized payers.

00.30.50.81.1612.1616.8621.5626.2630.9Total payments ($M)Concentration (HHI, 0-10,000)
Harrow Eye, LLC (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Harrow Eye, LLC's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Harrow Eye, LLC.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Harrow Eye, LLC.

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Harrow Eye, LLC ranks #602 of 1,925 by all-tracks total payments, led by "Food and Beverage".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Harrow Eye, LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.